Evidence map›Paper›PMID 39297417›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing.

Zhiquan Liu, Siyu Chen, Alexander E Davis, Chien-Hui Lo, Qing Wang, Tingting Li, Ke Ning, Qi Zhang, Jingyu Zhao, Sui Wang and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Molecular therapy. Nucleic acids · 2025
    Review
  5. [Advancements in CRISPR-Cas9 for Fanconi anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Review
  6. Article
  7. Precise Correction of theResearch (Washington, D.C.) · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhiquan LiuDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.ORCID 0000-0001-5433-5656
Siyu ChenDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Alexander E DavisDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Chien-Hui LoDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Qing WangDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Tingting LiDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Ke NingDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Qi ZhangDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Jingyu ZhaoDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Sui WangDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Yang SunDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.ORCID 0000-0001-8735-4765

Funding

The role of primary cilia in glaucoma pathogenesisR01EY025295 · NEI · STANFORD UNIVERSITY · PI Yang Sun · 2016 to 2026
$3.5M
Phosphoinositide signaling in glaucoma: rescue strategies for Lowe syndromeR01EY032159 · NEI · STANFORD UNIVERSITY · PI SUN, YANG · 2021 to 2024
$1.6M
Shedding light on glaucoma: optogenetics regulation of ciliary phosphoinositidesI01CX001481 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI SUN, YANG · 2017 to 2025
–
Children's Health Research Institute AwardCSRD VA I01 CX001481International Retinal Research FoundationNEI NIH HHS R01 EY025295NEI NIH HHS R01 EY032159NIH HHS R01-EY025295NIH HHS R01-EY032159P30 NIH grantResearch for Prevention of Blindness Unrestricted grantVA CX001481VA Merit BX-006638
6 · The paper itself

Abstract

Retinitis pigmentosa (RP) is a complex spectrum of inherited retinal diseases marked by the gradual loss of photoreceptor cells, ultimately leading to blindness. Among these, mutations in PDE6A, responsible for encoding a cGMP-specific phosphodiesterase, stand out as pivotal in autosomal recessive RP (RP43). Unfortunately, no effective therapy currently exists for this specific form of RP. However, recent advancements in genome editing, such as base editing (BE) and prime editing (PE), offer a promising avenue for precise and efficient gene therapy. Here, it is illustrated that the engineered BE and PE systems, particularly PE, exhibit high efficiency in rescuing a target point mutation with minimal bystander effects in an RP mouse model carrying the Pde6a (c.2009A > G, p.D670G) mutation. The optimized BE and PE systems are first screened in N2a cells and subsequently assessed in electroporated mouse retinas. Notably, the optimal PE system, delivered via dual adeno-associated virus (AAV), precisely corrects the pathogenic mutation with average 9.4% efficiency, with no detectable bystander editing. This correction restores PDE6A protein expression, preserved photoreceptors, and rescued retinal function in Pde6a mice. Therefore, this study offers a proof-of-concept demonstration for the treatment of Pde6a-related retinal degeneration using BE and PE systems.

Indexed as

Cyclic Nucleotide Phosphodiesterases, Type 6Disease Models, AnimalGene EditingGenetic TherapyRetinal DegenerationAnimalsEye ProteinsMiceRetinaRetinitis PigmentosaCyclic Nucleotide Phosphodiesterases, Type 6Eye ProteinsPde6a protein, mousebase editing (BE)pde6aprime editing (PE)retinal degeneration

Identifiers

PMID39297417
PMCPMC11558111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.